# Qitan Tech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/qitan-tech

- Industry: Biotechnology
- Headquarters: Chengdu, China
- Website: www.qitantech.com
- Total disclosed funding: $191M
- Latest round: Series C (Dec 28, 2023)
- Investors on record: 17

## About

Based in Chengdu, China, and established in 2016, Chengdu Qitan Technology Co., Ltd., trading as Qitan Tech, is a biotechnology company that focuses on gene sequencing and gene diagnostics through nanotechnology. The founder, Dr. Bai Jinwei, is a postdoctoral fellow in the IBM Watson Laboratory. The company released the domestic nanopore gene sequencer QNome-9604 in 2020. The branch offices were set up in Beijing, Chengdu, and other places. In August 2023, QPursue, a medium flux nanopore sequencing platform was released. In December 2025, Qitan Tech raised a venture funding from Zhongguancun Venture Capital and Beishang Capital.

The company’s products include nanopore sequencing, nanopore sequencers, flowcells & reagents, and nanopore sequencing software. The products can be used in pathogen research, tumor research genetic disease research, and so on. Its technology is applied in fields of biopharmaceuticals, pathogen infection, rare diseases, cancer detection, reproductive health, and agricultural and animal husbandry economies.

The company's revenue is generated by providing nanopore sequencers.

## Funding rounds

- Series C, Dec 28, 2023, $14M — BIO-TOWN Capital, Orinno Capital
- Series C, Dec 23, 2022, $100M — Huagai Capital, Meituan, Inc., BioTrack Capital
- Series B, Jun 8, 2021, $63M — CDH Investments, Hillhouse Investment, Huagai Capital, Gaorong Ventures, Yinxinggu Capital, Baidu Ventures, Alwin Capital, Riverhead Capital, BioTrack Capital, Zhongguancun Co-Innovative Fund Management, Boyuan Capital
- Series A, May 13, 2020, $14M — Gaorong Ventures, Yinxinggu Capital, Alwin Capital
- Angel, Feb 1, 2017, $0.4M — T-Capital, Qm Angel Investment, Empower Investment

## Investors

- T-Capital — Angel
- Qm Angel Investment — Angel
- Empower Investment (https://capitalatlas.ai/funds/empower-investment) — Angel
- Gaorong Ventures (https://capitalatlas.ai/funds/gaorong-ventures) — Series A, Series B
- Yinxinggu Capital (https://capitalatlas.ai/funds/yinxinggu-capital) — Series A, Series B
- Alwin Capital — Series A, Series B
- CDH Investments (https://capitalatlas.ai/funds/cdh-investments) — Series B
- Hillhouse Investment (https://capitalatlas.ai/funds/hillhouse-investment) — Series B
- Huagai Capital (https://capitalatlas.ai/funds/huagai-capital) — Series B, Series C
- Baidu Ventures (https://capitalatlas.ai/funds/baidu-ventures) — Series B
- Riverhead Capital (https://capitalatlas.ai/funds/riverhead-capital) — Series B
- BioTrack Capital (https://capitalatlas.ai/funds/biotrack-capital) — Series B, Series C
- Zhongguancun Co-Innovative Fund Management (https://capitalatlas.ai/funds/zhongguancun-co-innovative-fund-management) — Series B
- Boyuan Capital (https://capitalatlas.ai/funds/boyuan-capital) — Series B
- Meituan, Inc. — Series C
- BIO-TOWN Capital (https://capitalatlas.ai/funds/bio-town-capital) — Series C
- Orinno Capital (https://capitalatlas.ai/funds/orinno-capital) — Series C